ID: ALA2049092

Max Phase: Preclinical

Molecular Formula: C10H12N2O3

Molecular Weight: 208.22

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc2c(c1)N(O)C(=O)[C@@H](N)C2

Standard InChI:  InChI=1S/C10H12N2O3/c1-15-7-3-2-6-4-8(11)10(13)12(14)9(6)5-7/h2-3,5,8,14H,4,11H2,1H3/t8-/m0/s1

Standard InChI Key:  DTOYJWLYYMSLDG-QMMMGPOBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 208.22

Molecular Weight (Monoisotopic): 208.0848

AlogP: 0.30

#Rotatable Bonds: 1

Polar Surface Area: 75.79

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.40

CX Basic pKa: 7.35

CX LogP: -0.37

CX LogD: -0.46

Aromatic Rings: 1

Heavy Atoms: 15

QED Weighted: 0.65

Np Likeness Score: 0.28

References

1. Dounay AB, Anderson M, Bechle BM, Campbell BM, Claffey MM, Evdokimov A, Evrard E, Fonseca KR, Gan X, Ghosh S, Hayward MM, Horner W, Kim JY, McAllister LA, Pandit J, Paradis V, Parikh VD, Reese MR, Rong S, Salafia MA, Schuyten K, Strick CA, Tuttle JB, Valentine J, Wang H, Zawadzke LE, Verhoest PR..  (2012)  Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia.,  3  (3): [PMID:24900455] [10.1021/ml200204m]

2. Tuttle JB, Anderson M, Bechle BM, Campbell BM, Chang C, Dounay AB, Evrard E, Fonseca KR, Gan X, Ghosh S, Horner W, James LC, Kim JY, McAllister LA, Pandit J, Parikh VD, Rago BJ, Salafia MA, Strick CA, Zawadzke LE, Verhoest PR..  (2013)  Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions.,  4  (1): [PMID:24900560] [10.1021/ml300237v]

Source

Source(1):

• Scientific Literature